Codexis, Inc. (CDXS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 69 | 105 | 139 | 70 | 59 | 70 | 78 | 74 |
| Operating profit | $m | -38 | -24 | ||||||
| Net profit | $m | -24 | -21 | -34 | -76 | -65 | -44 | -31 | -33 |
| EPS reported | $ | -0.50 | -0.34 | ||||||
| Operating cashflow per share | $ | -0.22 | -0.11 | ||||||
| Capex per share | $ | 0.05 | 0.02 | ||||||
| FCF per share | $ | -0.27 | -0.13 | ||||||
| Free cash flow | $m | -24 | -12 | ||||||
| Net debt | $m | -38 | -14 | ||||||
| Book value equity | $m | 51 | 33 | ||||||
| Book value per share | $ | 0.58 | 0.36 | ||||||
| Number of shares | m | 87.14 | 91.05 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.81 | 4.31 | ||||||
| P/S LTM | x | 2.02 | 1.83 | ||||||
| P/FCF LTM | x | -5.96 | -11.66 | ||||||
| EV/EBITDA LTM | x | -4.86 | -7.61 | ||||||
| EV/Sales LTM | x | 2.34 | 2.61 | ||||||
| Earnings Yield LTM | % | -30.96% | -23.11% | ||||||
| FCF Yield | % | -16.79% | -8.57% | ||||||
| Quality | |||||||||
| ROE | % | -87.03% | -74.36% | ||||||
| ROIC | % | -30.56% | -22.69% | ||||||
| Operating margin | % | -54.46% | -31.23% | ||||||
| Gross margin | % | +86.73% | +83.71% | ||||||
| FCF/Sales | % | -33.88% | -15.68% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +18.61% | +30.89% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.33 | -0.17 | ||||||
| Net Debt/EBITDA | x | -0.66 | -2.10 | ||||||
| EBIT/Net interest | x | -7.96 | -18.77 | ||||||
| Net debt/market cap | % | +28.23% | +26.03% | ||||||
| Net debt/Equity | x | -0.75 | -0.43 | ||||||
| Gross debt/equity | x | 1.45 | 2.20 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free